Literature DB >> 19917920

Central neck dissection for papillary thyroid cancer.

Michael A Rosenbaum1, Christopher R McHenry.   

Abstract

OBJECTIVE: To examine the role of central neck dissection (CND) in patients with papillary thyroid cancer (PTC).
DESIGN: Retrospective analysis of patients treated for PTC between 1993 and 2008.
SETTING: Academic institution. PATIENTS: All patients diagnosed with PTC who underwent surgical therapy at our institution. MAIN OUTCOME MEASURES: Recurrence, hypocalcemia, hypoparathyroidism, and recurrent laryngeal nerve (RLN) injury.
RESULTS: A total of 136 patients were treated for PTC, 26 of whom were excluded because their initial resection was performed at another institution. Of the 110 patients who underwent initial surgical therapy, CND was performed in 22 patients (20%), 18 with and 4 without enlarged nodes at the time of surgery. A mean (SD) of 11 (4) lymph nodes were removed, and lymph node metastases were identified in 17 patients (77%). One patient developed a recurrence in the lateral neck at 15 months' follow-up. Eighty-eight patients had no abnormal lymph nodes and did not undergo CND, 2 of whom developed a recurrence (2%) (P = .49) in the central neck at 14 months' and 11 years' follow-up. Permanent RLN injury occurred in no patient who underwent CND and in 1 patient without a CND (1%). Transient hypocalcemia occurred in 19 patients who underwent CND (86%) compared with 54 patients without a CND (61%) (P = .01). Permanent hypoparathyroidism occurred in 1 patient who underwent a CND (5%).
CONCLUSION: After total thyroidectomy and CND, recurrence in the central neck is uncommon, but hypocalcemia is more common, raising questions about the use of routine CND in patients with PTC.

Entities:  

Mesh:

Year:  2009        PMID: 19917920     DOI: 10.1001/archoto.2009.158

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  27 in total

Review 1.  Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Juan J Sancho; Thomas W Jay Lennard; Ivan Paunovic; Frédéric Triponez; Antonio Sitges-Serra
Journal:  Langenbecks Arch Surg       Date:  2013-12-19       Impact factor: 3.445

2.  Surgery. Papillary thyroid cancer--how aggressive should surgery be?

Authors:  Sarah E Tevis; Herbert Chen
Journal:  Nat Rev Endocrinol       Date:  2015-02-17       Impact factor: 43.330

3.  Sentinel node biopsy in papillary thyroid cancer--what is the potential?

Authors:  S P Balasubramanian; J Brignall; H Y Lin; T J Stephenson; J Wadsley; B J Harrison; W L Craig; L Smart; Z Krukowski
Journal:  Langenbecks Arch Surg       Date:  2014-01-21       Impact factor: 3.445

Review 4.  Nodal metastases in thyroid cancer: prognostic implications and management.

Authors:  Laura Y Wang; Ian Ganly
Journal:  Future Oncol       Date:  2016-03-07       Impact factor: 3.404

Review 5.  Morbidity of central neck dissection for papillary thyroid cancer.

Authors:  Davide Lombardi; Remo Accorona; Alberto Paderno; Carlo Cappelli; Piero Nicolai
Journal:  Gland Surg       Date:  2017-10

Review 6.  Advances in surgical therapy for thyroid cancer.

Authors:  Haggi Mazeh; Herbert Chen
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

7.  Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases.

Authors:  Alexandre Bozec; Olivier Dassonville; Emmanuel Chamorey; Gilles Poissonnet; Anne Sudaka; Isabelle Peyrottes; Francette Ettore; Juliette Haudebourg; Françoise Bussière; Danielle Benisvy; Pierre-Yves Marcy; Jean Louis Sadoul; Paul Hofman; Sandra Lassale; Jacques Vallicioni; François Demard; José Santini
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-05-24       Impact factor: 2.503

8.  Is minimal residual lymph node disease in papillary thyroid cancer of prognostic impact? An analysis of the epithelial cell adhesion molecule EpCAM in lymph nodes of 40 pN0 patients.

Authors:  Alexander Rehders; Martin Anlauf; Ilona Adamowsky; Markus H Ghadimi; Sarah Klein; Christina Antke; Kenko Cupisti; Nikolas H Stoecklein; Wolfram T Knoefel
Journal:  Pathol Oncol Res       Date:  2013-08-06       Impact factor: 3.201

9.  Predictive Value of BRAFV600E Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis.

Authors:  Jing-Yong Song; Shi-Ran Sun; Fang Dong; Tao Huang; Bin Wu; Jing Zhou
Journal:  Curr Med Sci       Date:  2018-10-20

10.  Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND.

Authors:  Ali S Alzahrani; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2013-01-21       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.